Gazyva (obinutuzumab) 1000 mg/40 mL concentrate for solution for infusion Showing Chronic lymphocytic leukemia (CLL) Follicular lymphoma (FL) Targeted cancer therapy. Delivery of medicines from Europe within 4-5 days, +380996042415 Viber, Whatsapp.

Display

Chronic lymphocytic leukemia (CLL)

Gaziva® in combination with chlorambucil is indicated for the treatment of adult patients with chronic lymphocytic leukemia, who have not previously recovered from the treatment and may have concomitant illness, which is inconvenient conducting therapy based on fludarabine in higher doses.

Folicular lymphoma (FL)

Gaziva® in combination with chemotherapy with further supportive therapy with the drug Gazyva®, in the current version, is indicated for the treatment of patients with previously not glamorous widespread follicular lymphoma.

Gaziva® in combination with bendamustine followed by supportive therapy with Gazyva® is indicated for the treatment of patients with follicular lymphoma, who did not respond to treatment with rituximab or to combination therapy that included rituximab, and whose illness progressed within an hour or over a period of 6 months after treatment with rituximab or after combination therapy, which included rituximab.